Patent · US Active

ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors

US9545418B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

THE JOHNS HOPKINS UNIVERSITY · US

Inventors

Antonio Jimeno · Englewood, US
Manuel Hidalgo · Brignais, FR

Key dates

Filing date	Feb 17, 2015
Grant date	Jan 17, 2017
Priority date	—
Expiry date	Feb 17, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction of stabilization of at least one sign or symptom of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.